|Phase 1, open label, cohort study of CAVATAKTM (Coxsackievirus A21) given intravenously to stage IV patients bearing ICAM-1 expressing solid tumours||EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Dublin, Ireland.||6-9 November 2012|
Scientific Presentations 2012
© Viralytics Limited 2018
This information does not take your circumstances into account. Read the relevant ASX releases, financial reports and prospectuses before making an investment decision. Shares in Viralytics Limited, ABN 12 010 657 351, are traded on the Australian Stock Exchange (ASX:VLA) and on the over-the-counter market (OTC: VRACY).